Okwangoku, i-COVID-19 ikwimeko yobhubhani kwihlabathi liphela. Ukwahluka kweDelta kunye ne-Omicron kuxhaphakile, okukhokelela kuphuculo oluqhubekayo lwesakhono sazo sosulelo. Phakathi kwamaza aphindaphindiweyo e-COVID-19, ukongeza kwisitofu sokugonya se-COVID-19, uphuhliso lwamachiza omlomo asebenzayo e-COVID-19 kunye neendlela zovavanyo ezikhawulezayo, ezilula neziyintshayo ziye zaba yimfuno entsha yothintelo nolawulo lobhubhane. IViva Biotech Holdings kunye ne-XLement, etyalwe yaza yamiliselwa yiViva BioInnovator, izibophelele ekuveliseni amayeza omlomo e-COVID-19 kunye novavanyo lwentsholongwane, inegalelo kumlo ochasene nobhubhani we-COVID-19.
ILanghua Pharmaceutical isayina isivumelwano kunye ne-MPP ukuvelisa into eluhlaza ye-COVID-19 yeyeza lokuthomalalisa iintsholongwane i-molnupiravir.
Jan 2022, iMedicines Patent Pool (MPP) yabhengeza ukuba ityikitye izivumelwano kunye neenkampani ezininzi zokwenza igeneric kuquka iZhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), i-subsidiary yeViva biotech holdings (Viva Biotech (01873.HK)) ukwenzela ukuba ukwenziwa kwamayeza onyango e-COVID-19 e-Molnupiravir kunye nokubonelela kumazwe ali-105 anengeniso ephantsi naphakathi (LMICs) ukuququzelela ufikelelo olufikelelekayo kwihlabathi jikelele lwe-molnupiravir kunye nokuxhasa uthintelo nolawulo lobhubhane. Iinkampani ezintlanu ziya kugxila ekuveliseni izithako ezikrwada, iinkampani ezili-13 ziya kuvelisa zombini isithako esikrwada kunye nechiza eligqityiweyo kwaye iinkampani ezili-9 ziya kuvelisa ichiza eligqityiweyo.
I-Medicines Patent Pool (MPP) ngumbutho wezempilo karhulumente oxhaswa yiZizwe eziManyeneyo osebenza ukwandisa ufikelelo, kwaye uququzelele uphuhliso lwamayeza asindisa ubomi kumazwe anengeniso ephantsi kunye nephakathi. I-MPP kunye ne-MSD, igama lokuthengisa le-Merck & Co., Inc Kenilworth NJ USA yatyikitya isivumelwano selayisenisi ngokuzithandela ngo-Oct 2021. Phantsi kwemiqathango yesivumelwano, i-MPP, ngelayisenisi enikwe yi-MSD, iya kuvunyelwa ukuba iqhubekisele phambili ilayisenisi engabodwa. iilayisenisi eziya kubavelisi (“iLayisensi ye-MPP”) kunye nesiseko sokwenza izinto ezahlukeneyo zonikezelo lwe-molnupiravir eqinisekiswe umgangatho kumazwe aphantsi kweLayisensi ye-MPP, ngokuxhomekeke kugunyaziso lolawulo lwasekhaya.
I-Molnupiravir (MK-4482 kunye ne-EIDD-2801) luhlobo lophando, olulawulwa ngomlomo lwe-analog ye-ribonucleoside enamandla ethintela ukuphindaphinda kwe-SARS-CoV-2 (i-arhente engunobangela we-COVID-19). I-Molnupiravir iphuhliswa yi-MSD ngentsebenziswano ne-Ridgeback Biotherapeutics, liyeza lokuqala elithathwa ngomlomo le-antiviral elifumanekayo kunyango lwe-COVID-19. Idatha evela kwiSigaba sesi-3 i-MOVe-OUT ibonise ukuba unyango lwakwangoko nge-molnupiravir luwunciphise kakhulu umngcipheko wokulaliswa esibhedlele okanye ukusweleka kumngcipheko omkhulu, abantu abadala abangagonywanga abane-COVID-19.
Ngokwe-MPP, iinkampani ezibonelelwe ngelayisenisi zibonise ngempumelelo ukukwazi kwazo ukuhlangabezana neemfuno ze-MPP ezinxulumene nomthamo wemveliso, ukuthotyelwa kwemithetho, kunye nokukwazi ukuhlangabezana nemigangatho yamazwe ngamazwe yamayeza aqinisekisiweyo ngokomgangatho. Ugunyaziso olunikezelwe kwiLanghua Pharmaceutical yi-MPP imele ukuqinisekiswa okuphezulu kunye nokuqatshelwa kwinkqubo yophuhliso kunye nokwandisa ii-APIs, ukubonelela ngokuzinzileyo, i-GMP kunye nenkqubo ye-EHS.
IKhithi yoVavanyo ye-Xlement's COVID-19 iLuphumelele uHlolo lweSebe lezeNzululwazi kunye neTekhnoloji yeRiphabhlikhi yase-China ngempumelelo
Ngomhla wesi-2 kuMatshi ka-2022, i-Xlement, inkampani ezinikeleyo ye-NanoSPR biochip kunye nezixhobo zebhayoloji yenkampani ebikade ityale imali yaze yafukanyelwa yi-Viva BioInnovator, yafumana isaziso sokuphumelela uvavanyo lokusebenza kwi-Ofisi yoMphathiswa wezeNzululwazi nobuChwepheshe kwiRiphabhlikhi yaBantu baseTshayina. Iprojekthi yayo "i-R&D kunye neMveliso yeMisa yeNanoSPR COVID-19 Isixhobo soVavanyo lweNqanaba" yenye yeeprojekthi eziphambili "zoThintelo loMngcipheko woluNtu kunye noLawulo kunye neTekhnoloji yokuPhendula ngokuNgxamisekileyo kunye neZixhobo" inkqubo esebenza indima ebalulekileyo kwi-COVID-19- uphando lwezenzululwazi olunxulumeneyo oluqhubekayo eTshayina. Ngokuphumelela kwayo ekuhlolweni, iXlement's COVID-19 Test Kit nayo iye yaqinisekiswa yiEuropean Union CE ngemveliso enkulu yexesha elizayo kwaye iza kusetyenziswa kungekudala.
Ixhaswe kwitekhnoloji ye-chip ye-NanoSPR ekhethekileyo, i-Xlement iphuhlise ikiti yovavanyo yamasuntswana e-COVID-19, evumela uvavanyo lwenyathelo elinye le-antigens ezininzi zeentsholongwane kwiisampulu ezingama-96 kwimizuzu eli-15, kwaye ubuntununtunu busondele ekuvavanyeni i-antigen enye. Le ndlela ibonisa iinzuzo ezinkulu xa kuthelekiswa neendlela zokuvavanya i-viral nucleic acid ekhoyo: ingasetyenziselwa ukuzivavanya ekhaya, inciphisa ixesha lokuvavanya kakhulu, ngaloo ndlela, inciphisa kakhulu iindleko zokuvavanya i-reagents kunye nomsebenzi. Ngokwamkelwa ngakumbi kobuchwephesha be-NanoSPR kuvavanyo lwe-COVID-19 oluphuhliswe yi-Xlement, silindele ukubona ukuxilongwa kwangoko ngokukhawuleza kweesampulu ezikrokrelekayo kunye novavanyo olukhawulezileyo kwindawo enkulu.
INTO ONOKUYITHATHA KWELI NQAKU:
- On March 2nd, 2022, Xlement, a devoted NanoSPR biochip and instruments biotech company that previously invested and incubated by Viva BioInnovator, received the notice of passing the performance evaluation from the Ministry of Science and Technology of the People´s Republic of China.
- Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers (“MPP Licence”) and diversify the manufacturing base for the supply of quality-assured molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
- Amid the repeated waves of COVID-19, in addition to COVID-19 vaccine, the development of effective oral COVID-19 drugs and rapid, simple and innovative testing methods have also become a new demand for current epidemic prevention and control.
